欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2020, Vol. 25 ›› Issue (12): 1363-1368.doi: 10.12092/j.issn.1009-2501.2020.12.007

• 临床药理学 • 上一篇    下一篇

空腹和餐后状态下盐酸西替利嗪片的生物等效性研究#br#

胡朝英1,郜丹1,高琳艳1,宛燕飞2,高蓓2,李林1,张兰1   

  1. 1首都医科大学宣武医院药学部,I期临床研究中心,国家老年疾病临床医学研究中心,北京 100053;2成都利尔药业有限公司,成都 610083,四川

  • 收稿日期:2020-03-20 修回日期:2020-06-25 出版日期:2020-12-26 发布日期:2021-01-04
  • 通讯作者: 张兰,女,博士生导师,教授,主要从事临床药理学和神经药理学研究。 Tel: 010-83199071 E-mail: zhanglan@xwhosp.org
  • 作者简介:胡朝英,女,博士,主管药师,主要从事新药临床研究。 Tel: 010-83199073 E-mail: huchaoying@xwhosp.org
  • 基金资助:
    国家“重大新药创制”科技重大专项(2017ZX09101001-002-044);北京市医院管理中心“登峰”计划专项经费资助(DFL20190803);首都科技领军人才(Z191100006119017)

Bioequivalence study of cetirizine hydrochloride tablets under fasting and fed conditions

HU Chaoying 1, GAO Dan 1, GAO Linyan 1, WAN Yanfei 2, GAO Bei 2, LI Lin1, ZHANG Lan1   

  1. 1 Department of Pharmacy, Phase I Clinical Trial Center, Xuanwu Hospital Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing 100053, China; 2 Chengdu Leer Pharmaceutical Co., Ltd, Chengdu 610083, Sichuan, China
  • Received:2020-03-20 Revised:2020-06-25 Online:2020-12-26 Published:2021-01-04

摘要: 目的:评价中国健康人群空腹和餐后状态下口服盐酸西替利嗪片的生物等效性。方法:采用单剂量、随机、开放、两制剂、两周期、交叉对照的试验设计,健康受试者每周期在空腹或餐后状态下口服受试制剂和参比制剂盐酸西替利嗪片10 mg。采用经验证的液相色谱-串联质谱(LC-MS/MS)法测定西替利嗪的血浆浓度,使用WinNonlin 6.3计算药动学参数并用SAS 9.4软件进行生物等效性评价。结果:空腹状态下,受试制剂和参比制剂中西替利嗪Cmax分别为(402±84)、(379±53)  ng/mL,AUC0-t分别为(2 520±491)、(2 455±480) ng·mL-1·h,AUC0-∞分别为(2 623±483)、(2 608±441) ng·mL-1·h。餐后状态下,受试制剂和参比制剂中西替利嗪Cmax分别为(221± 55)、(221±36)ng/mL,AUC0-t分别为(2 046±524)、(2 067±513) ng·mL-1·h,AUC0-∞分别为(2 142±508)、(2 165±500) ng·mL-1·h。受试制剂和参比制剂西替利嗪Cmax、AUC0-t和AUC0-∞几何均值比的90%置信区间均在80.00%~125.00%的生物等效性范围内。结论:盐酸西替利嗪片受试制剂和参比制剂在空腹和餐后状态下均具有生物等效性。

关键词: 西替利嗪, 药动学, 生物等效性, 液相色谱-串联质谱

Abstract: AIM: To evaluate the pharmacokinetics and bioequivalence of cetirizine hydrochloride tablets under fasting and fed conditions in Chinese healthy subjects.  METHODS: This was a randomized, open-label, double-sequence, two-period, crossover designed study, and healthy subjects enrolled and administrated a single dose of 10 mg test and reference cetirizine hydrochloride tablets in each period under fasting or fed condition. The plasma concentrations of cetirizine were determined by a validated LC-MS/MS method. The pharmacokinetic parameters were calculated with WinNonlin 6.3 and the bioequivalence was evaluated through SAS 9.4 software. RESULTS: In the fasting condition, the major pharmacokinetic parameters of cetirizine of test and reference formulations were as follows, Cmax were (402±84) and (379±53) ng/mL, AUC0-t were (2 520±491) and (2 455±480) ng·mL-1·h, AUC0-∞ were (2 623±483) and (2 608±441) ng·mL-1·h, respectively. Subjects administrated test and reference formulations in fed condition had a Cmax of (221±55) and (221±36) ng/mL, an AUC0-t of (2 046±524) and (2067±513) ng·mL-1·h, AUC0-∞ were (2 142±508) and (2 165±500) ng·mL-1·h, respectively. The 90% confidence intervals of geometric mean ratios were all within the bioequivalence range of 80.00%-125.00%. CONCLUSION: The test formulation of cetirizine hydrochloride was bioequivalent to the reference product both under fasting and fed conditions.

Key words: cetirizine, pharmacokinetic, bioequivalence, LC-MS/MS

中图分类号: